5AM Venture Management, LLC — 13F Holdings & Portfolio
CIK 1799883 · latest 13F-HR filed 2026-05-15
5AM Venture Management, LLC manages $360.2M in 13F-reported U.S. long-equity assets across 20 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are ERAS (15.66%), TRDA (14.21%), TYRA (10.94%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 2 new positions, exited 3, added to 11, and trimmed 5.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$360.2M
Long-equity book
20
Distinct positions
2026-03-31
Filed 2026-05-15
+2 / −3 / ↑11 / ↓5
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ERASCA INC$36.3M +180.5%
- TYRA BIOSCIENCES INC$12.4M +45.7%
- ENTRADA THERAPEUTICS INC$9.5M +22.8%
- CENTESSA PHARMACEUTICALS PLC$8.5M +58.8%
- TECTONIC THERAPEUTIC INC$6.1M +48.2%
Top Trims
- CAMP4 THERAPEUTICS CORP-$10.1M -28.1%
- EYEPOINT INC-$5.6M -29.4%
- BIOHAVEN LTD-$2.1M -25.1%
- SKYE BIOSCIENCE INC-$1.3M -18.0%
- SILENCE THERAPEUTICS PLC-$385.7K -13.3%
Exited Positions
- VIRIDIAN THERAPEUTICS INC$22.9M
- ENLIVEN THERAPEUTICS INC$11.9M
- RALLYBIO CORP$2.5M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ERASCA INC | ERAS | 29479A108 | $56.4M | 15.66% | 3,485,971 | SH |
| 2 | ENTRADA THERAPEUTICS INC | TRDA | 29384C108 | $51.2M | 14.21% | 4,056,379 | SH |
| 3 | TYRA BIOSCIENCES INC | TYRA | 90240B106 | $39.4M | 10.94% | 1,029,298 | SH |
| 4 | CAMP4 THERAPEUTICS CORP | CAMP | 13463J101 | $25.9M | 7.19% | 5,869,091 | SH |
| 5 | CENTESSA PHARMACEUTICALS PLC | CNTA | 152309100 | $23.1M | 6.41% | 580,945 | SH |
| 6 | PHARVARIS N V | PHVS | N69605108 | $22.5M | 6.26% | 797,600 | SH |
| 7 | MAPLIGHT THERAPEUTICS INC | MPLT | 56565P103 | $19.3M | 5.36% | 950,011 | SH |
| 8 | TECTONIC THERAPEUTIC INC | TECX | 878972108 | $18.8M | 5.21% | 606,660 | SH |
| 9 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $15.8M | 4.38% | 497,270 | SH |
| 10 | ARTIVA BIOTHERAPEUTICS INC | ARTV | 04317A107 | $15.2M | 4.21% | 2,353,304 | SH |
| 11 | EYEPOINT INC | EYPT | 30233G209 | $13.5M | 3.76% | 1,050,000 | SH |
| 12 | SURROZEN INC | SRZN | 86889P208 | $11.3M | 3.13% | 387,500 | SH |
| 13 | ZENTALIS PHARMACEUTICALS INC | ZNTL | 98943L107 | $9.2M | 2.56% | 3,947,913 | SH |
| 14 | GH RESEARCH PLC | GHRS | G3855L106 | $8.1M | 2.24% | 572,665 | SH |
| 15 | PROTARA THERAPEUTICS INC | TARA | 74365U107 | $7.1M | 1.98% | 1,369,782 | SH |
| 16 | BIOHAVEN LTD | BHVN | G1110E107 | $6.3M | 1.74% | 738,972 | SH |
| 17 | ALX ONCOLOGY HLDGS INC | ALXO | 00166B105 | $6.1M | 1.70% | 3,057,325 | SH |
| 18 | SKYE BIOSCIENCE INC | SKYE | 83086J200 | $6.0M | 1.65% | 9,681,763 | SH |
| 19 | RALLYBIO CORP | RLYB | 75120L209 | $2.6M | 0.73% | 291,788 | SH |
| 20 | SILENCE THERAPEUTICS PLC | SLN | 82686Q101 | $2.5M | 0.70% | 476,200 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $360.2M | 20 | 0001799883-26-000002 |
| 2025-12-31 | 2026-02-17 | $318.1M | 21 | 0001799883-26-000001 |
| 2025-09-30 | 2025-11-14 | $273.0M | 25 | 0001799883-25-000002 |